Fluarix

January 17, 2013
Tools

Vaccine: Fluarix
Company: GlaxoSmithKline
Approval Date: Fluarix
Protects Against: Influenza

GlaxoSmithKline ($GSK) ramped up vaccine production with the development of a $300 million vaccine manufacturing facility in Pennsylvania in 2009. Not to be confused with GSK's newest flu vaccine, Fluarix Quadrivalent, Fluarix protects against three flu strains and is approved for those age 3 and older. Fluarix and FluLaval together reached £230 million ($369.9 million) worldwide in 2011. Sales of the pair grew specifically in the United States, showing a 25% jump from the year before to £132 million ($212.2 million). Not bad for a vaccine first approved in 2005.

For more:
GSK unveils $300M vax facility for U.S. market push
GSK kickstarts global trial for seasonal flu vax
Agency OKs Fluarix, opening spigot of vaccine supplies

Special Report: Major FDA vaccine approvals of 2012
Press Releases
  • Heart Failure Study Performed by Cleveland Clinic Shows Serial Testing with Cardiac Biomarker ST2 Predicts Outcomes of Hospitalized Patients
  • Novasep and Celladon execute MYDICAR API supply agreement
  • Building a Stronger Network in the Fight Against Cancer
  • New Data Confirming Patient Satisfaction, Safety, Efficacy and Reduction of Hospital Readmissions with ActiveCare® Mobile Compression Device Following Joint Replacement Surgery Presented at AAOS Annual Meeting
  • Presage Biosciences Appoints Brad Margus to Board of Directors
  • More Press Releases
Featured Jobs
> Need a job? Need to hire? Visit our jobs site.